AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14734063
Drug: 5-fluorouracil (25mg/ml)
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-fluorouracil (25mg/ml) treatment for 5 minutes
Trial: 31318748
Drug: Extracorporeal shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shock wave therapy (n = 32)
Trial: 28061321
Drug: Subcutaneous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous vitamin E ointment application (Group 1)
Trial: 28061321
Drug: No vitamin
RxNorm normalized name: Vitamin B12 NOS
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No vitamin E ointment application (Group 2)
Trial: 26001670
Drug: Integrative cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative cognitive behavioral therapy for PGD (PG-CBT)
Trial: 21129746
Drug: Non-users of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-users of lipid-lowering treatment (LLT)
Trial: 19413147
Drug: PLMS indexes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLMS indexes of children who were medication free for a third and fourth night (n = 7) or just a third night (n = 2)
Trial: 17388751
Drug: Inhalation technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation technique
Trial: 17388751
Drug: Inhalation resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation resistance
Trial: 15220017
Drug: Diazepam (0.28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.28 mg/kg IV)
Trial: 11231977
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen, 0.625 mg/day
Trial: 9748117
Drug: 5FU dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5FU dose adjusted according to the 5FU area under the curve (AUC0‐48h; PK‐arm)
Trial: 9748117
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of 5FU (St‐arm; 4 g/m2)
Trial: 8040918
Drug: Alcohol Skills
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol Skills Training Program (ASTP), a cognitive behavioral approach, details of dosage and duration not specified.
Trial: 18356686
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg) + Propranolol (80 mg)
Trial: 16609087
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (various regimens including cyclophosphamide, doxorubicin, fluorouracil, and paclitaxel) for ER-negative tumors
Trial: 16609087
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (various regimens including cyclophosphamide, doxorubicin, fluorouracil, and paclitaxel) for ER-positive tumors
Trial: 16609087
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy for ER-negative tumors
Trial: 16609087
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy for ER-positive tumors
Trial: 10780142
Drug: Child in
RxNorm normalized name: Pro Comfort Child Inhaler Spacer Chamber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child in remission from cancer and no longer undergoing treatment (RCL)
Trial: 10780142
Drug: Child in
RxNorm normalized name: Pro Comfort Child Inhaler Spacer Chamber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child in remission and still undergoing treatment (RCTL)
Trial: 1471706
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol treatment for 6 weeks
Trial: 6718766
Drug: Neurotensin infusion
RxNorm normalized name: neurotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurotensin infusion at 3 pmol X kg‐1 X min‐1 for 4 h
Trial: 6718766
Drug: Neurotensin infusion
RxNorm normalized name: neurotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurotensin infusion
Trial: 23096033
Drug: Cytoflavin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoflavin (2 tablets twice a day) and standard therapy (acetylsalicylic acid and antihypertensive drugs)
Trial: 23096033
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (acetylsalicylic acid and antihypertensive drugs)
Trial: 16802767
Drug: Montelukast (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (5 mg daily)
Trial: 17623754
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (400 microg per day in two doses)
Trial: 12124481
Drug: AGAb bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGAb bone marrow immunoscintigraphy (370 MBq of (99m)Tc labelled anti‐NCA‐95 antigranulocyte antibodies)
Trial: 7825764
Drug: Concurrent review
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent review classification
Trial: 385399
Drug: mianserin 30‐60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mianserin 30‐60 mg daily
Trial: 385399
Drug: diazepam 15‐30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diazepam 15‐30 mg daily
Trial: 25840004
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group received an intranasal dose of 'serotonin' (placebo) prior to the second stress test.
Trial: 23827259
Drug: Low-dose naltrexone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose naltrexone (192 mg)
Trial: 23827259
Drug: High-dose naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose naltrexone (384 mg)
Trial: 17692720
Drug: Varenicline 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline 0.25 mg BID
Trial: 17692720
Drug: Varenicline 0.5
RxNorm normalized name: varenicline 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline 0.5 mg BID
Trial: 17692720
Drug: Varenicline (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (all doses)
Trial: 11281235
Drug: Calcium-blocking drugs
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-blocking drugs
Trial: 19248130
Drug: Sequential monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential monotherapy
Trial: 11281235
Drug: ACE inhibitors,
RxNorm normalized name: ACE INHIBITORS, PLAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors, calcium-blocking drugs, diuretics
Trial: 4907514
Drug: Ampicillin, 1
RxNorm normalized name: Ampicillin, 1 g injectable powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin, 1 g. four times a day for 28 days
Trial: 4907514
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in identical capsules for 28 days
Trial: 23725973
Drug: L-carnitine-containing peritoneal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine-containing peritoneal dialysis solution (0.1%, 2 g/bag)
Trial: 23725973
Drug: Standard glucose-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard glucose-based solution (1.5% or 2.5%)
Trial: 23725973
Drug: L-carnitine-containing solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine-containing solution
Trial: 23725973
Drug: Standard glucose-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard glucose-based solution
Trial: 17615905
Drug: Zinc plus
RxNorm normalized name: Zinc plus Copper
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc plus multivitamin syrup
Trial: 17615905
Drug: Multivitamin syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin syrup
Trial: 12926799
Drug: Beta-carotene (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (25 mg) twice daily for 36 months
Trial: 12926799
Drug: Placebo (saccharose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saccharose capsules)
Trial: 12213867
Drug: Nateglinide 60
RxNorm normalized name: nateglinide 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide 60 mg
Trial: 10868832
Drug: Nateglinide 180
RxNorm normalized name: nateglinide 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide 180 mg
Trial: 20446252
Drug: Intrarectal lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrarectal lidocaine gel (10 cc of 2% lidocaine)
Trial: 20446252
Drug: Periprostatic nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periprostatic nerve block (10 cc of 1% lidocaine solution)
Trial: 20446252
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 cc of ultrasound gel)
Trial: 1833126
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose oral contraceptives (20 micrograms ethinyl estradiol and 150 micrograms desogestrel per day)
Trial: 1833126
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose oral contraceptives (50 micrograms ethinyl estradiol and 125 micrograms desogestrel per day)
Trial: 1833126
Drug: Control (before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (before drug ingestion)
Trial: 6285744
Drug: Conjugated estrogens
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated estrogens (1.25 mg daily, orally)
Trial: 6285744
Drug: Percutaneous estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Percutaneous estradiol (5 gm ointment, 3 mg E2, applied each evening)
Trial: 26245498
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone agonist (GnRHa) goserelin, which causes a net decrease in sex-steroid levels.
Trial: 26245498
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone agonist (GnRHa) goserelin
Trial: 25267532
Drug: Carers' assessment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carers' assessment, skills and information sharing (C) intervention + treatment as usual (TAU)
Trial: 17287932
Drug: Probiotic Escherichia
RxNorm normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic Escherichia coli Nissle 1917 (EcN) solution, 1-3 ml per day (10^8 viable EcN cells per millilitre)
Trial: 17287932
Drug: Probiotic Escherichia
RxNorm normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic Escherichia coli Nissle 1917 (EcN) solution
Trial: 12811371
Drug: Serotonin treatment
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonin treatment
Trial: 10556126
Drug: Acetazolamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (250 mg by mouth, every 8 hours for 3 days)
Trial: 6177441
Drug: Aprotinin therapy
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprotinin therapy added to hypovolaemia treatment
Trial: 30865917
Drug: Oral targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral targeted therapy or chemotherapy
Trial: 28461543
Drug: Anxiety levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anxiety levels (measured daily with a visual analog scale)
Trial: 28461543
Drug: Sedative exposure
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sedative exposure (daily sedation intensity score and sedative dose frequency)
Trial: 23806013
Drug: Waiting list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting list group reassessed after five weeks, then randomly assigned to one of the two treatments.
Trial: 10764365
Drug: Nurse prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse prescriptions
Trial: 10764365
Drug: Doctor prescriptions
RxNorm normalized name: Doctor's Choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doctor prescriptions
Trial: 8968035
Drug: Clodronate 1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clodronate 1600 mg daily by mouth
Trial: 1293650
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg) - two doses (the previous night and before surgery)
Trial: 1293650
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg) - two doses (the previous night and before surgery)
Trial: 1293650
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg) - the night prior to surgery
Trial: 1293650
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg) - the night before
Trial: 1293650
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg) - two doses (the previous night and before surgery)
Trial: 6085358
Drug: Nifedipine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (1.0 mg intravenous)
Trial: 6085358
Drug: Nitrendipine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (1.0 mg intravenous)
Trial: 26773917
Drug: Pharmacotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy plus physical exercise (n=7)
Trial: 26773917
Drug: Only pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only pharmacotherapy (n=7)
Trial: 22588010
Drug: Brief intensified
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief intensified cognitive behavioral therapy (CBT) and/or pharmacotherapy
Trial: 12239942
Drug: 5‐isosorbide mononitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐isosorbide mononitrate (80 mg/day)
Trial: 2147621
Drug: 40‐80 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40‐80 mg ketanserin daily for 4 months
Trial: 30487058
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin therapy for primary prevention of atherosclerotic events
Trial: 26072302
Drug: Periarticular anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periarticular anesthesia (ropivacaine 1% 20 mL)
Trial: 26072302
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and intravenous analgesia alone
Trial: 24246210
Drug: Imidafenacin 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imidafenacin 0.1 mg twice daily for 12 weeks
Trial: 24246210
Drug: Fesoterodine 4
RxNorm normalized name: fesoterodine 4 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine 4 mg once daily for 12 weeks
Trial: 12473833
Drug: d4T (stavudine)
RxNorm normalized name: STAVUDINE (d4T)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d4T (stavudine) in combination with lamivudine and indinavir
Trial: 12473833
Drug: ZDV (zidovudine)
RxNorm normalized name: ZDV
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ZDV (zidovudine) in combination with lamivudine and indinavir
Trial: 510206
Drug: VAC chemotherapy
RxNorm normalized name: VAC-52150
DrugBank: VAC-52150 (DB17781)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAC chemotherapy (vincristin, adriamycin, cyclophosphamide)
Trial: 510206
Drug: FMC chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMC chemotherapy (fluorouracil, methotrexate, cyclophosphamide)
Trial: 31418908
Drug: e-CBT (cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: e-CBT (cognitive behavioural therapy with an email-based recording and reminding system for 20 days)
Trial: 31418908
Drug: s-CBT (cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: s-CBT (cognitive behavioural therapy with a sticky note reminder for 20 days)
Trial: 20179692
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (diet, exercise, laxatives)
Trial: 15042229
Drug: Insecticide-treated curtains
RxNorm normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insecticide-treated curtains (ITC) provided to half the population in 1994, with re-treatment or replacement annually.
Trial: 3518625
Drug: Ampicillin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin (4 g)
Trial: 24396842
Drug: Laser-Lok type
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser-Lok type implants (n = 39)
Trial: 24396842
Drug: Non-Laser-Lok type
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-Laser-Lok type implants (n = 39)
Trial: 20203244
Drug: Intranasal fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal fluticasone propionate, 200 microg twice a day for 3 days after 14 days of oxymetazoline
Trial: 20203244
Drug: Intranasal oxymetazoline,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal oxymetazoline, 200 microg three times a day for 14 days
Trial: 20203244
Drug: Oral prazosin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prazosin, 1 mg
Trial: 17653243
Drug: Angiotensin inhibition
RxNorm normalized name: Angiotensin 1-7
DrugBank: Angiotensin 1-7 (DB11720)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin inhibition (ACE inhibitor or angiotensin receptor blocker)
Trial: 15799687
Drug: Etanercept 25
RxNorm normalized name: etanercept 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 25 mg twice weekly, alone or in combination with methotrexate
Trial: 12553620
Drug: Prompt‐L‐Pop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prompt‐L‐Pop
Trial: 369515
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg ethynodiol diacetate + 0.1 mg mestranol ('Ovulen')
Trial: 29189955
Drug: Intra‐ and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra‐ and peri‐articular blood injection (Group A)
Trial: 29189955
Drug: Peri‐articular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peri‐articular injection alone (Group B)
Trial: 24828894
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (perindopril ± indapamide)
Trial: 11840080
Drug: CMV gB/MF59
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMV gB/MF59 vaccine (20 microg)
Trial: 8907724
Drug: Twice-daily enteric-coated
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily enteric-coated sodium valproate tablets
Trial: 8907724
Drug: Twice-daily controlled
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily controlled release tablets (Epilim Chrono)
Trial: 8907724
Drug: Once-daily controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily controlled release tablets (Epilim Chrono)
Trial: 30360014
Drug: Etoricoxib 120
RxNorm normalized name: etoricoxib 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 120 mg under fasted conditions
Trial: 30360014
Drug: Etoricoxib 120
RxNorm normalized name: etoricoxib 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 120 mg under fed conditions
Trial: 28566209
Drug: Half-dose TKI
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose TKI therapy (imatinib 200 mg daily, dasatinib 50 mg daily, or nilotinib 200 mg twice daily) for 12 months
Trial: 26475066
Drug: Early salvage
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early salvage radiation therapy
Trial: 26475066
Drug: 3-dimensional conformal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-dimensional conformal radiation therapy
Trial: 29145540
Drug: Pioglitazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (30 mg daily)
Trial: 10422927
Drug: 10 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml/kg intravenous fluid
Trial: 10422927
Drug: 2 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml/kg intravenous fluid
Trial: 8665556
Drug: Apomorphine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine 1.5 mg
Trial: 15134988
Drug: Apomorphine 3
RxNorm normalized name: apomorphine 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine 3 mg
Trial: 1688044
Drug: Oxatomide gel
RxNorm normalized name: oxatomide
DrugBank: Oxatomide (DB12877)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxatomide gel at 5%
Trial: 1688044
Drug: Dechlorpheniramine cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dechlorpheniramine cream at 1%
Trial: 6642380
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg orally in the evening and 400 mg intramuscularly two hours prior to induction of anesthesia
Trial: 18451780
Drug: No specific
RxNorm normalized name: Oregano specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No specific medication (Control)